[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![bryan_johnson Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::17468569.png) Bryan Johnson [@bryan_johnson](/creator/twitter/bryan_johnson) on x 624.5K followers
Created: 2025-06-26 15:34:26 UTC

7/ Limitations and what’s next
+ IV infusions every XX weeks
Current regimen requires clinic visits; Lilly is developing a single sub-cutaneous co-formulation with tirzepatide to match pen-style convenience and possibly add further fat-loss potency with the dual GIP-GLP1 agonism.

+ Modest, transient LDL-cholesterol rise
Needs confirmation in larger cardiovascular-outcome studies now planned for 2027 read-out.

+ Muscle volume checked, but muscle strength still to be assessed
Phase-3 and extension studies will add strength tests and, in a subset, muscle biopsies.

+ Phase X sample size and duration
Global Phase X trials (obesity, diabetes and older-adult cohorts) begin enrolling in the second half of 2025 to confirm durability (longer dosing protocol and follow up) and capture rare adverse events (larger sample size, higher statistical power).


XXXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1938259566221004848/c:line.svg)

**Related Topics**
[transient](/topic/transient)
[bryan johnson](/topic/bryan-johnson)

[Post Link](https://x.com/bryan_johnson/status/1938259566221004848)